SCHEMBL4236704

SCHEMBL4236704

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.66
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
PARP10 Q53GL7 6/20 0.51
ALDH1A1 P00352 3/20 0.51
PARP15 Q460N3 2/20 0.51
KMT2A Q03164 1/20 0.51
PARP14 Q460N5 1/20 0.51
PARP16 Q8N5Y8 1/20 0.51
PARP11 Q9NR21 1/20 0.51
PARP4 Q9UKK3 1/20 0.51
MAPK1 P28482 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227928 0.86 PKM (0.69) PKMCYP2C9CYP2C19ALDH1A1MAPK1
SCHEMBL4235398 0.86 PKM (0.55) PKMCYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL4229112 0.85 PKM (0.57) PKMALDH1A1KMT2ASMN1; SMN2NPC1
SCHEMBL4236662 0.84 PKM (0.50) PKMPARP10ALDH1A1KMT2AMAPK1
SCHEMBL4236717 0.82 PKM (0.54) PKMCYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL4242067 0.82 PKM (0.48) PKMCYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL4785954 0.79 KMT2A (0.70) PKMCYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL4233255 0.79 PKM (0.59) PKMCYP2C9CYP2C19ALDH1A1MAPK1
SCHEMBL4242397 0.78 PKM (0.65) PKMCYP2C9CYP2C19ALDH1A1MAPK1
SCHEMBL4236682 0.78 PKM (0.64) PKMCYP2C9CYP2C19ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885CYP2C9 1439/4885CYP2C19 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.